Skip to main content
Premium Trial:

Request an Annual Quote

Natera, DiagCor Sign Deal to Bring Panorama NIPT to Hong Kong

NEW YORK (GenomeWeb News) – Natera today announced it has reached a deal with DiagCor to launch Natera's non-invasive prenatal screening test in Hong Kong.

DiagCor is based in Hong Kong and provides molecular diagnostic testing to doctors and healthcare professionals in the region.

The deal further expands the reach of Natera's test called Panorama into international markets and follows similar deals with the DASA Group and Hospital Israelita Albert Einstein to bring the test to Brazil, and with LifeLabs to make the Panorama available in Canada. In June Natera signed a distribution agreement with Unilabs covering Switzerland and Scandinavia.

Panorama uses a blood draw to detect trisomy 21, 18, and 13, as well as monosomy X, triploidy, and sex chromosome aneuploidies. It employs Natera's algorithm called Next Generation Aneuploidy Test Using SNPs to analyze the cell-free DNA from both the mother and the fetus.

Financial and other terms of today's deal were not disclosed.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.